Clinical Trials Logo

Filter by:
NCT ID: NCT06411769 Recruiting - Physical Activity Clinical Trials

Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas

Start date: August 2025
Phase: N/A
Study type: Interventional

The investigators will test if the 50,000 for Life (50K4Life) is effective at improving walking engagement in school employees in 30 public schools by delivering a two-phased adaptive intervention to improve walking engagement in school workers in 30 public schools. In Phase 1, all study schools will be randomly assigned to a 50K4Life only, or 50K4Life + SMS Text Messaging group. In Phase 2, non-responder schools will be randomly assigned to one of two 6-month adaptive treatments: a) an individual-level intervention that includes remote education modules (REM) and one-to-one monthly phone-based coaching, or, b) a school-level intervention that includes group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and work time/weekend group walks/hikes. The schools that 50% or more participants who achieve 50,000 steps in one week will continue with the Phase 1 condition. Intervention strategies will be coordinated by health educators and managed using the Pathverse app. Data collection will occur at baseline, 8 weeks (Phase 2 randomization decision point), 8 months (immediate post intervention), 12 months (4 months post-intervention), and 18 months (10 months post-intervention) for a total of 18 months of study participation.

NCT ID: NCT06411756 Not yet recruiting - Clinical trials for Colorectal Neoplasms

Physical Activity Centers Empowerment

PACE
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This research study tests the feasibility of the Physical Activity Centers Empowerment (PACE) physical activity intervention for African American individuals diagnosed with colorectal cancer. Feasibility will be measured as intervention reach, effectiveness, adoption, implementation, and maintenance. Seventy-two subjects will be recruited to conduct a pilot two-group, randomized repeated measures study.

NCT ID: NCT06411730 Recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and drug levels of orally administered BMS-986368 in healthy participants, healthy elderly participants, and healthy participants of japanese ethnicity.

NCT ID: NCT06411704 Recruiting - Frailty Clinical Trials

Remote Exercise Video Adaptations to Maximize Physical Activity in Childhood Cancer

Start date: May 2024
Phase:
Study type: Observational

The goal of this observational study is to leverage childhood cancer survivor input to adapt video content of a digital video disc-(DVD) delivered evidence-based PA intervention, originally designed for community-dwelling older adults. Primary Objective: - To leverage childhood cancer survivor input to adapt video content for an evidence-based remote exercise intervention.

NCT ID: NCT06411691 Not yet recruiting - Colorectal Cancer Clinical Trials

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Start date: August 2024
Phase: Phase 2
Study type: Interventional

Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcinoma (PDAC) patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).

NCT ID: NCT06411613 Recruiting - Clinical trials for Chronic Kidney Diseases

Home-based Conservative Care Model for Advanced Kidney Disease

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This is a randomized pilot study to test the feasibility and acceptability of a novel conservative care (CC) pathway among patients with advanced chronic kidney disease (CKD) who have chosen to forgo initiation of maintenance dialysis, their caregivers and providers.

NCT ID: NCT06411548 Not yet recruiting - Clinical trials for Type 1 Diabetes Mellitus

Insulearn Feasibility With MDI

InsuLearn
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This is a 24-hour, randomized, crossover, single-center trial where participants are randomized to either start with the InsuLearn intervention or the usual care (UC) intervention. In the InsuLearn intervention, insulin doses are optimized using data collected in a 4-weeks at home data collection period.

NCT ID: NCT06411431 Recruiting - Clinical trials for Primary Spontaneous Pneumothorax

Early Chest Tube Removal After Surgery for Primary Spontaneous Pneumothorax: A Randomized Controlled Trial

Start date: October 3, 2023
Phase: N/A
Study type: Interventional

Video-assisted thoracoscopic surgery (VATS) with blebectomy/wedge resection plus pleurodesis is the standard of care for recurrent primary spontaneous pneumothorax (PSP) or, in certain instances, after the first episode. The chest tube from surgery is typically kept to suction until post-operative day (POD) 2 to allow for scarring of the lung to the chest to prevent recurrence. However, the scarring process takes place over a period of weeks and is there no data to support POD#2 as the best time to remove the chest tube. Also, shorter chest tube duration can lower length of stay, patient discomfort, and hospital cost. The goal of this randomized study is to determine if early removal (POD#1) of chest tube after video-assisted thoracoscopic surgery (VATS) with blebectomy/wedge resection plus chemical pleurodesis for primary spontaneous pneumothorax (PSP): - has no worse 2-year recurrence rate compared to standard removal (POD#2) - will lower length of stay compared to standard removal - will result in less complications or re-interventions compared to standard removal Participants will be asked to join prior to surgery. Following standard-of-care surgery, participants will be screened for randomization. If still eligible, participants will be randomized for early chest tube removal or standard removal. Early Removal will happen within 24 hours after surgery, with Standard Removal happening day 2 after surgery. Participants will follow-up with the study team for 2 years on the following schedule: - In clinic with a chest x-ray 2 weeks after surgery - By phone 3 months after surgery - In clinic with a chest x-ray 1 year after surgery - In clinic with a chest x-ray 2 years after surgery

NCT ID: NCT06411418 Recruiting - Clinical trials for Intracranial Aneurysms

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm

SHIELD
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms

NCT ID: NCT06411379 Recruiting - Clinical trials for Hidradenitis Suppurativa

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Start date: May 14, 2024
Phase: Phase 3
Study type: Interventional

This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.